+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies



Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies



Current Medical Research and Opinion 2019: 1-11



To compare the multi-biomarker disease activity (MBDA) score with the DAS28-CRP and CRP for predicting risk of radiographic progression in patients with rheumatoid arthritis. Published studies of the MBDA score and radiographic progression with ≥100 patients per cohort were evaluated. Rates of radiographic progression over 1 year were determined across the low/moderate/high categories for MBDA score (low/moderate/high: <30, 30-44, >44), DAS28-CRP (low/moderate/high: ≤2.67, >2.67-4.09, >4.09) and CRP (low/moderate/high: ≤10, >10-30, >30 mg/L), with positive and negative predictive value (PPV, NPV) and relative risk (RR) determined for high vs. not-high (i.e. low and moderate combined) categories. Patient-level data from studies having all three measures was pooled to: (1) determine a combined RR for radiographic progression in the high vs. not-high categories for each measure; and (2) compare the predictive ability of MBDA score vs. DAS28-CRP by comparing the rates of radiographic progression observed in subgroups created by cross-classifying the high and not-high categories of each measure. Five cohorts were identified for inclusion (total N=929). In each, radiographic progression was more frequent with increasing MBDA scores. Among the three cohorts with requisite data, PPVs were generally similar using categories of MBDA score, DAS28-CRP or CRP but NPVs were greater for MBDA score (93-97%) than DAS28-CRP or CRP (77-87%). RRs for radiographic progression were greater when based on categories of MBDA score than DAS28-CRP or CRP and the combined RR was greater for MBDA score (4.6, p < .0001) than DAS28-CRP (1.7, p = .02) or CRP (1.7, p = .002). For patients cross-classified by MBDA score and DAS28-CRP, high vs. not-high MBDA score significantly predicted radiographic progression independently of DAS28-CRP. High and not-high MBDA scores were associated with increased and low risk, respectively, for radiographic progression over one year. MBDA score was a better predictor of radiographic progression than DAS28-CRP or CRP.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066507409

Download citation: RISBibTeXText

PMID: 30777458

DOI: 10.1080/03007995.2019.1585064


Related references

Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. Arthritis Care and Research 71(11): 1459-1472, 2019

Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology 55(2): 357-366, 2016

THU0145A multi-biomarker disease activity (MBDA) score measures rheumatoid arthritis disease activity in patients treated with the JAK inhibitor tofacitinib. Annals of the Rheumatic Diseases 71(Suppl 3): 204.2-204, 2013

A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology 52(7): 1202-1207, 2013

AB0247Associations of a Multi-Biomarker Disease Activity Score with Clinical and Radiographic Parameters in Rheumatoid Arthritis. Annals of the Rheumatic Diseases 74(Suppl 2): 974.1-974, 2015

FRI0042Validation of A Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis in Relation to Imaging Inflammation and Damage. Annals of the Rheumatic Diseases 73(Suppl 2): 396.2-396, 2014

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. Arthritis Research and Therapy 20(1): 256, 2018

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatology 56(6): 973-980, 2017

Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score. Nihon Rinsho Men'eki Gakkai Kaishi 39(1): 37-41, 2016

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scandinavian Journal of Rheumatology 48(1): 9, 2019

Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. Journal of Rheumatology 37(12): 2566-2572, 2010

Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. Scandinavian Journal of Rheumatology 46(5): 353-358, 2017

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. Plos one 13(5): E0192425, 2018

Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?. Annals of the Rheumatic Diseases 74(11): 2097-2099, 2015

FRI0132 A multi-biomarker disease activity score (the vectra DA algorithm score) reflects clinical remission for rheumatoid arthritis (RA) in the best study. Annals of the Rheumatic Diseases 71(Suppl 3): 355-355, 2012